Immune Reconstitution of Immunosuppressed Sepsis Patients
Status:
Terminated
Trial end date:
2017-11-13
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blinded, placebo-controlled study of two dosing frequencies
of recombinant Interleukin-7 (CYT107) treatment to restore absolute lymphocyte counts in
sepsis patients; IRIS-7A (Immune Reconstitution of Immunosuppressed Sepsis patients).
A parallel study will be performed in United State of America to allow a common statistical
analysis of the primary end points and analysis for the enrolled patient population.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Limoges
Collaborators:
Revimmune Vanderbilt University Vanderbilt University Medical Center